Pilatus Biosciences expands into Hong Kong
Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary…
Samsung Plans to Acquire Swiss Active Ingredient Manufacturer
For 1.5 billion The Swiss active ingredient manufacturer Polypeptide is set to be acquired by a company belonging…
Nurix Q2 revenue $9M; Roche deal up to $2.3B
Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a major global collaboration with Roche for BTK…
Patent cliff fuels Novartis’ $1.5bn swoop for London biotech
Monday 06 July 2026 6:16 pm Myricx has developed a new platform for antibody-drug conjugates Swiss pharmaceutical giant…
Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market
A Fosun Pharma subsidiary has paid Junshi Biosciences 215 million yuan ($32 million) for Chinese rights to a near-approval…
Evommune’s phase 2b flops, ending challenge to Novartis in hives
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis…
Top Stories from Western Switzerland (June 2026)
From a world-leading deeptech funding ranking to a landmark watchmaking laboratory and major life sciences raises, discover Western…
Roche Challenges Illumina with Axelios Gene Sequencer Launch
Swiss pharmaceutical behemoth Roche has unveiled its long-anticipated Axelios gene sequencer, stepping into the next-generation sequencing market dominated…
Antares Therapeutics Enters Agreement with Novartis to Develop First-in-Class Cancer Therapies
Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop and commercialize small-molecule therapies for…
Genentech pens $420M deal for Omass’ preclinical IBD program
Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical…
Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies
Roche is licensing out part of its cancer platform to Chinese biotech Innovent Biologics. Innovent gains nonexclusive access…
Sanofi becomes latest pharma to hold fire on UK R&D
Sanofi has become the latest Big Pharma to freeze R&D investment decisions in the U.K., while Roche confirmed…